Last reviewed · How we verify
Trimethoprim (TRIMETHOPRIM)
Trimethoprim is a dihydrofolate reductase inhibitor antibacterial small molecule originally developed by Mutual Pharm and currently owned by Dr Reddys Labs Sa. It targets dihydrofolate reductase, an enzyme essential for bacterial DNA synthesis, thereby inhibiting bacterial growth. Trimethoprim is approved to treat various bacterial infections, including urinary tract infections, bronchitis, and conjunctivitis. The drug has a high bioavailability of 98% and a half-life of 9.6 hours. It is off-patent, with multiple generic manufacturers available.
At a glance
| Generic name | TRIMETHOPRIM |
|---|---|
| Sponsor | Dr Reddys Labs Sa |
| Drug class | Sulfonamide Antimicrobial [EPC] |
| Target | Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Acute exacerbation of chronic bronchitis
- Acute otitis media
- Bacterial conjunctivitis
- Bacterial urinary infection
- Blepharoconjunctivitis
- Escherichia coli urinary tract infection
- Haemophilus Influenzae Acute Otitis Media
- Haemophilus Influenzae Chronic Bronchitis
- Infective otitis media
- Klebsiella cystitis
- Morganella Morganii Urinary Tract Infection
- Pneumocystis Carinii Pneumonia Prevention
- Pneumocystosis jiroveci pneumonia
- Proteus urinary tract infection
- Shigellosis
- Staphylococcus Aureus Urinary Tract Infection
- Streptococcus Pneumoniae Chronic Bronchitis
- Urinary tract infectious disease
Common side effects
- abdominal pain
- diarrhea
- vomiting
- rash
- pruritus
- exfoliative dermatitis
- epigastric distress
- nausea
- glossitis
- thrombocytopenia
- leukopenia
- neutropenia
Drug interactions
- pralatrexate
Key clinical trials
- Prophylactic Antibiotics for Outpatient Urethral Bulking (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) (PHASE2)
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trimethoprim CI brief — competitive landscape report
- Trimethoprim updates RSS · CI watch RSS
- Dr Reddys Labs Sa portfolio CI